Phosphoinositide 3-kinase signaling is critical for ErbB3-driven breast cancer cell motility and metastasis

Oncogene

Volumn 31, Issue 6, 2012, Pages 706-715

  Smirnova, T ^a   Zhou, Z N ^a   Flinn, R J ^a   Wyckoff, J ^a   Boimel, P J ^a   Pozzuto, M ^a   Coniglio, S J ^a   Backer, J M ^a   Bresnick, A R ^a,b   Condeelis, J S ^a   Hynes, N E ^a   Segall, J E ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b FRIEDRICH MIESCHER INSTITUTE FOR BIOMEDICAL RESEARCH   (Switzerland)

Author keywords

breast cancer; ErbB3; in vivo invasion; intravasation; metastasis; PI3 Kinase

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 3; NEU DIFFERENTIATION FACTOR; NEU DIFFERENTIATION FACTOR BETA 1; PHENYLALANINE; PHOSPHATIDYLINOSITOL 3 KINASE; PIK 75; PROTEIN P85; TYROSINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING SITE; BREAST CANCER; CARBOXY TERMINAL SEQUENCE; CELL INVASION; CELL MOTILITY; CHEMOTAXIS; ENDOTHELIUM; METASTASIS; MULTIPHOTON MICROSCOPY; MUTATIONAL ANALYSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; TUMOR GROWTH;

ANIMALS; BINDING SITES; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; FEMALE; HUMANS; HYDRAZONES; IMMUNOPRECIPITATION; MAMMARY NEOPLASMS, ANIMAL; MICE; MICE, SCID; MICROSCOPY, FLUORESCENCE, MULTIPHOTON; MUTATION; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEUREGULIN-1; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; PROTEIN BINDING; RATS; RECEPTOR, ERBB-3; SIGNAL TRANSDUCTION; SULFONAMIDES; TRANSPLANTATION, HETEROLOGOUS; TYROSINE;

EID: 84856960963     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2011.275     Document Type: Article

References (37)

1. Adam L, Vadlamudi R, Kondapaka SB, Chernoff J, Mendelsohn J, Kumar R. (1998). Heregulin regulates cytoskeletal reorganization and cell migration through the p21-activated kinase-1 via phosphatidylinositol-3 kinase. J Biol Chem 273: 28238-28246. (Pubitemid 28496122)
2. Amin DN, Campbell MR, Moasser MM. (2010). The role of HER3, the unpretentious member of the HER family, in cancer biology and cancer therapeutics. Semin Cell Dev Biol 21: 944-950.
3. Baselga J, Swain SM. (2009). Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer 9: 463-475.
4. Burgess AW. (2008). EGFR family: structure physiology signalling and therapeutic targets. Growth Factors 26: 263-274.
5. Cain RJ, Ridley AJ. (2009). Phosphoinositide 3-kinases in cell migration. Biol Cell 101: 13-29.
6. Campbell MR, Amin D, Moasser MM. (2010). HER3 comes of age: new insights into its functions and role in signaling, tumor biology, and cancer therapy. Clin Cancer Res 16: 1373-1383.
7. Chandarlapaty S, Sawai A, Scaltriti M, Rodrik-Outmezguine V, Grbovic-Huezo O, Serra V et al. (2011). AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity. Cancer Cell 19: 58-71.
8. Chausovsky A, Waterman H, Elbaum M, Yarden Y, Geiger B, Bershadsky AD. (2000). Molecular requirements for the effect of neuregulin on cell spreading, motility and colony organization. Oncogene 19: 878-888. (Pubitemid 30153745)
9. Chaussade C, Rewcastle GW, Kendall JD, Denny WA, Cho K, Gronning LM et al. (2007). Evidence for functional redundancy of class IA PI3K isoforms in insulin signalling. Biochem J 404: 449-458. (Pubitemid 46953919)
10. Chiu CG, Masoudi H, Leung S, Voduc DK, Gilks B, Huntsman DG et al. (2010). HER-3 overexpression is prognostic of reduced breast cancer survival: a study of 4046 patients. Annals of Surgery 251: 1107-1116.
11. Di Cosimo S, Baselga J. (2010). Management of breast cancer with targeted agents: importance of heterogeneity. [corrected]. Nat Rev Clin Oncol 7:139-147.
12. Engelman JA, Janne PA, Mermel C, Pearlberg J, Mukohara T, Fleet C et al. (2005). ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines. Proc Natl Acad Sci USA 102: 3788-3793. (Pubitemid 40354690)
13. Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO et al. (2007). MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316: 1039-1043. (Pubitemid 46799492)
14. Fiddes RJ, Campbell DH, Janes PW, Sivertsen SP, Sasaki H, Wallasch C et al. (1998). Analysis of Grb7 recruitment by heregulin-activated erbB receptors reveals a novel target selectivity for erbB3. J Biol Chem 273: 7717-7724. (Pubitemid 28152802)
15. Fujimoto N, Wislez M, Zhang J, Iwanaga K, Dackor J, Hanna AE et al. (2005). High expression of ErbB family members and their ligands in lung adenocarcinomas that are sensitive to inhibition of epidermal growth factor receptor. Cancer Res 65: 11478-11485. (Pubitemid 41821705)
16. Hayakawa M, Kawaguchi K, Kaizawa H, Koizumi T, Ohishi T, Yamano M et al. (2007). Synthesis and biological evaluation of sulfonylhydrazone-substituted imidazo[1,2-a]pyridines as novel PI3 kinase p110alpha inhibitors. Bioorg Med Chem 15: 5837-5844. (Pubitemid 47043472)
17. Hellyer NJ, Kim MS, Koland JG. (2001). Heregulin-dependent activation of phosphoinositide 3-kinase and Akt via the ErbB2/ErbB3 co-receptor. J Biol Chem 276: 42153-42161.
18. Hernandez L, Smirnova T, Kedrin D, Wyckoff J, Zhu L, Stanley ER et al. (2009a). The EGF/CSF-1 paracrine invasion loop can be triggered by heregulin beta1 and CXCL12. Cancer Res 69: 3221-3227.
19. Hernandez L, Smirnova T, Wyckoff J, Condeelis J, Segall JE. (2009b). in vivo assay for tumor cell invasion. Methods Mol Biol 571: 227-238.
20. Holbro T, Beerli RR, Maurer F, Koziczak M, Barbas III CF, Hynes NE. (2003). The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation. Proc Natl Acad Sci USA 100: 8933-8938. (Pubitemid 36899201)
21. Iivanainen E, Paatero I, Heikkinen SM, Junttila TT, Cao R, Klint P et al. (2007). Intra-and extracellular signaling by endothelial neuregulin-1. Exp Cell Res 313: 2896-2909. (Pubitemid 47126431)
22. Jones RB, Gordus A, Krall JA, MacBeath G. (2006). A quantitative protein interaction network for the ErbB receptors using protein microarrays. Nature 439: 168-174. (Pubitemid 43083134)
23. Kalinowski A, Plowes NJ, Huang Q, Berdejo-Izquierdo C, Russell RR, Russell KS. (2010). Metalloproteinase-dependent cleavage of neuregulin and autocrine stimulation of vascular endothelial cells. FASEB J 24: 2567-2575.
24. Kedrin D, Wyckoff J, Boimel PJ, Coniglio SJ, Hynes NE, Arteaga CL et al. (2009). ERBB1 and ERBB2 have distinct functions in tumor cell invasion and intravasation. Clin Cancer Res 15: 3733-3739.
25. Ky B, Kimmel SE, Safa RN, Putt ME, Sweitzer NK, Fang JC et al. (2009). Neuregulin-1 beta is associated with disease severity and adverse outcomes in chronic heart failure. Circulation 120: 310-317.
26. Neri A, Welch D, Kawaguchi T, Nicolson GL. (1982). Development and biologic properties of malignant cell sublines and clones of a spontaneously metastasizing rat mammary adenocarcinoma. J Natl Cancer Inst 68: 507-517. (Pubitemid 12156692)
27. Olayioye MA, Badache A, Daly JM, Hynes NE. (2001). An essential role for Src kinase in ErbB receptor signaling through the MAPK pathway. Exp Cell Res 267: 81-87. (Pubitemid 32579143)
28. Prigent SA, Gullick WJ. (1994). Identification of c-erbB-3 binding sites for phosphatidylinositol 30-kinase and SHC using an EGF receptor/c-erbB-3 chimera. Embo J 13: 2831-2841.
29. Sassen A, Rochon J, Wild P, Hartmann A, Hofstaedter F, Schwarz S et al. (2008). Cytogenetic analysis of HER1/EGFR, HER2, HER3 and HER4 in 278 breast cancer patients. Breast Cancer Res 10: R2.
30. Schade B, Lam SH, Cernea D, Sanguin-Gendreau V, Cardiff RD, Jung BL et al. (2007). Distinct ErbB-2 coupled signaling pathways promote mammary tumors with unique pathologic and transcriptional profiles. Cancer Res 67: 7579-7588. (Pubitemid 47281349)
31. Serra V, Scaltriti M, Prudkin L, Eichhorn PJ, Ibrahim YH, Chandarlapaty S et al. (2011). PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer. Oncogene 30: 2547-2557.
32. Siegel PM, Ryan ED, Cardiff RD, Muller WJ. (1999). Elevated expression of activated forms of Neu/ErbB-2 and ErbB-3 are involved in the induction of mammary tumors in transgenic mice: implications for human breast cancer. EMBO J 18: 2149-2164. (Pubitemid 29179172)
33. Vijapurkar U, Kim MS, Koland JG. (2003). Roles of mitogenactivated protein kinase and phosphoinositide 30-kinase in ErbB2/ErbB3 coreceptor-mediated heregulin signaling. Exp Cell Res 284: 291-302. (Pubitemid 36324536)
34. Wyckoff JB, Jones JG, Condeelis JS, Segall JE. (2000). A critical step in metastasis: in vivo analysis of intravasation at the primary tumor. Cancer Res 60: 2504-2511. (Pubitemid 30262445)
35. Wyckoff JB, Wang Y, Lin EY, Li JF, Goswami S, Stanley ER et al. (2007). Direct visualization of macrophage-assisted tumor cell intravasation in mammary tumors. Cancer Res 67: 2649-2656. (Pubitemid 46548952)
36. Xue C, Liang F, Mahmood R, Vuolo M, Wyckoff J, Qian H et al. (2006). ErbB3-dependent motility and intravasation in breast cancer metastasis. Cancer Res 66: 1418-1426. (Pubitemid 43259922)
37. Zhang J, Zhong W, Cui T, Yang M, Hu X, Xu K et al. (2006). Generation of an adult smooth muscle cell-targeted Cre recombinase mouse model. Arterioscler Thromb Vasc Biol 26: e23-e24.